Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jul;55(7):3621-3.
doi: 10.1128/AAC.00062-11. Epub 2011 Apr 18.

Relevance of timing for determination of posaconazole plasma concentrations

Werner J Heinz  1 , Janina Zirkel, Anna Kuhn, Diana Schirmer, Ulrike Lenker, Daniela Keller, Hartwig Klinker
Affiliations
Clinical Trial

Relevance of timing for determination of posaconazole plasma concentrations

Werner J Heinz et al. Antimicrob Agents Chemother. 2011 Jul.

Abstract

For posaconazole, drug monitoring is suggested, but the relevance of timing for the determination of posaconazole concentration (PC) remains unclear. We investigated the variation of PC before and 4 and 8 h after the administration of 400 mg of posaconazole. Mean concentrations were 645, 678, and 616 ng/ml. The differences between trough and maximum concentrations were below 20% in 17 and below 30% in 20 of 25 patients. Hence, untimed posaconazole plasma concentrations give reliable information for most patients.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Box plot of posaconazole concentrations (all patients) before and 4 and 8 h after medication (median, black bar; 50% interquartile range, white box).
Fig. 2.
Fig. 2.
Individual course of posaconazole concentrations.
Fig. 3.
Fig. 3.
Intraday maximum deviation of posaconazole concentrations in relation to the maximum concentration of the drug in serum (Cmax) (median, black bar; 50% interquartile range, white box).
See this image and copyright information in PMC

References

    1. Bohme A., et al. 2009. Treatment of invasive fungal infections in cancer patients—recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 88:97–110 - PubMed
    1. Bruggemann R. J., et al. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441–1458 - PubMed
    1. Bruggemann R. J., Touw D. J., Aarnoutse R. E., Verweij P. E., Burger D. M. 2009. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob. Agents Chemother. 53:303–305 - PMC - PubMed
    1. Cornely O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348–359 - PubMed
    1. Farowski F., et al. 2010. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob. Agents Chemother. 54:2928–2931 - PMC - PubMed

Publication types

LinkOut - more resources